Uppsala, Sweden – Strike Pharma, the company using its proprietary Adaptable Drug Affinity Conjugate (ADAC™) technology platform to develop individualized immunotherapeutic treatments, today announced the election of Dr. Niclas Stiernholm as Chairman of the Board at the company’s Annual General Meeting held on June 13^th.

Dr. Stiernholm brings more than 30 years of experience from the immunotherapy field. Since earning his Ph.D. in immunology at the University of Toronto, he has held numerous executive and board positions in biotechnology companies. Most recently he served as CEO for Trillium Therapeutics where he was instrumental in transitioning the organization from a discovery-based academic spin-out to a clinical-stage immuno-oncology company, listed on Nasdaq and the Toronto Stock Exchange.

Commenting on his appointment, Dr. Stiernholm said “The ADAC technology platform offers an exciting new approach to development of highly effective immunotherapeutic treatments. I very much look forward to supporting the company on its journey.”

Dr. Sara Mangsbo, Chief Scientific Officer and co-founder at Strike Pharma added, “We are extremely pleased to welcome Niclas to Strike Pharma. His experience will be invaluable as we accelerate our efforts to bring our first immune-oncology candidate to clinical trials and to further develop the ADAC technology platform.”

Today, Strike Pharma is focused on the development of novel, clinically-relevant candidates for use as immunotherapeutic vaccines in the treatment of solid tumors. By using ADAC technology, truly individualized treatments can be generated based on the genetic profile of each patient’s tumor. Such highly targeted treatment offers the potential to increase therapeutic efficacy and reduce dosage levels, thereby minimizing the risk of side effects.

About Strike Pharma (www.strikepharma.com)

Headquartered in Uppsala, Sweden, Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology to take precision medicine to a new level, enabling development of truly individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor. Such highly targeted treatment offers the potential to not only increase therapeutic efficacy, but also to reduce dosage levels thereby minimizing the risk of side effects.

Today, Strike Pharma’s development program is focused on selection of novel, clinically-relevant candidates for use as immunotherapeutic vaccines in the treatment of solid tumors. However, the company is confident that the ADAC technology platform has the potential to facilitate development of many other antibody-based therapeutics and that this novel approach will have a significant impact across a wide variety of disease indications within the rapidly developing field of personalized medicine.

Strike Pharma was founded in 2020 with the aim of commercializing ADAC technology. Investors include Eir Ventures, Flerie Invest, Uppsala University Invest, Almi Invest, SLU Invest and Monesi Förvaltnings.

Enquiries

Mårten Winge CEO

+46 (0) 70 657 59 27

[email protected]